Table 1. Baseline characteristics of the study participants.
| n = 122 | |
|---|---|
| Gender (male/female) | 72/50 |
| Age (years) | 61.0 ± 13.0 |
| BMI (kg/m2) | 26.4 ± 5.1 |
| Diabetes duration (years) | 10.7 ± 9.3 |
| Hypertension, n (%) | 73 (60) |
| Dislipidemia, n (%) | 89 (73) |
| SBP (mmHg) | 131.7 ± 17.7 |
| DBP (mmHg) | 75.1 ± 12.0 |
| History of smoking (%) | 60 (49) |
| Total cholesterol (mg/dL) | 187.4 ± 34.5 |
| Triglyceride (mg/dL) | 138.3 ± 70.2 |
| HDL cholesterol (mg/dL) | 52.2 ± 16.3 |
| LDL cholesterol (mg/dL) | 110.0 ± 30.0 |
| eGFR (ml/min per 1.73 m2) | 77.4 ± 23.6 |
| Fasting blood glucose (mg/dL) | 153.6 ± 51.1 |
| HbA1c (%) | 8.57 ± 2.33 |
| Urinary 8-isoprostane (pg/mgCr) | 265.2 ± 264.2 |
| Urinary 8-OHdG (ng/mgCr) | 11.4 ± 7.9 |
| MDA-LDL (U/dl) | 133.0 ± 42.3 |
| Nε-(carboxymethyl) lysine (µg/ml) | 3.49 ± 0.96 |
| 3-deoxyglucosone (ng/ml) | 24.37 ± 14.2 |
| max IMT (mm) | 1.64 ± 0.70 |
| mean baPWV (cm/s) | 1569.4 ± 311.4 |
| mean ABI | 1.13 ± 0.96 |
| Coronary artery calcification score, (AU) | 197.03 ± 412.78 |
| Skin autofluorescence (AU) | 2.42 ± 0.417 |
| Metformin, n (%) | 52 (43) |
| DPP-4 inhibitors, n (%) | 53 (44) |
| Statins, n (%) | 50 (41) |
| RAS inhibitors, n (%) | 61 (50) |
BMI, body mass index; SBP, systolic blood pressure; DBP, diastolic blood pressure; eGFR, estimated glomerular filtration rate; HbA1c, hemoglobinA1c; OHdG, hydroxydeoxyguanosine; MDA-LDL, malondialdehyde modified low density lipoprotein; IMT, intima-media thickness; baPWV, brachial ankle pulse wave velocity; ABI, ankle brachial index; DPP, dipeptidyl peptidase; RAS, renin-angiotensin system